June 10, 2025 Understanding Accounting and Bookkeeping Services for Business Success
May 27, 2025 How much does a Turkish passport cost?
May 22, 2025 How Measurement and Mix Modeling Drive Better Business Decisions
May 22, 2025 Are you making these mistakes when analyzing candlestick patterns?
April 23, 2025 Oleksandr Orlovskyi: Reviews, Biography, and All About Cryptocurrency
Eli Lilly and Comp. (LLY) Stock Forecast for 2025, 2026, 2027. Sell or Buy?
Updated: June 22, 2025 (01:59)
Sector: HealthcareThe share price of Eli Lilly and Company (LLY) now
News Impact Analyzer
Full report
This Week
|
Bullish | Impact: 5 | News: 15 (10/3/2) |
Previous Week
|
Bullish | Impact: 5 | News: 4 (2/2/0) |
Two Weeks Ago
|
Bullish | Impact: 5 | News: 3 (3/0/0) |
Three Weeks Ago
|
Bullish | Impact: 1.13 | News: 4 (1/2/1) |
Analysts predictions
Full report
This Week
|
Bullish | Opinions: 4 (4/0/0) |
Previous Week
|
Bullish | Opinions: 1 (1/0/0) |
Two Weeks Ago
|
Bullish | Opinions: 1 (1/0/0) |
Three Weeks Ago
|
Neutral | Opinions: 1 |
Analyzing the Most Important LLY news

Major Deals Stir the Market: Eli Lilly Acquires Verve Therapeutics!


Eli Lilly's Orforglipron Impresses in Phase 3 Trial with Weight Loss and Diabetes Control


Major Weight Loss Drug Trials Set to Shake Up the Obesity Market

Historical and forecast chart of Eli Lilly and Comp. stock
The chart below shows the historical price of Eli Lilly and Comp. stock and a prediction chart for the next month.
For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast,
and Weighted Average Best Forecast. Detailed values for the Eli Lilly and Comp. stock price can be found in the table below.
Long-term forecasts by years.
Eli Lilly and Company Analysts predictions review

Eli Lilly's strategic acquisition of Verve Therapeutics and its entry into the cardiovascular gene therapy sector highlight a clear commitment to innovation-led growth. The investment in GalNAc PCSK9 gene editing positions Lilly in a high-growth, high-potential market with transformative therapeutic applications. While regulatory risks and clinical success are key uncertainties, the acquisition enhances its R&D pipeline and diversifies revenue opportunities. Investor sentiment remains bullish, driven by future growth prospects, pipeline advancements, and prudent capital deployment. Near-term stock performance will depend on trial data and integration synergies, with long-term potential reinforced by the cardiovascular market's expansion.

Eli Lilly's Strategic Move: Evaluating the GalNAc PCSK9 Gene Editing Acquisition

Eli Lilly’s acquisition ties directly to the transformative potential of the GalNAc PCSK9 gene editing program, reflecting its ambition to expand its innovative footprint in cardiovascular treatments. The author points out that this program signals an entry into a competitive precision medicine market, with high reward potential but inherent execution risks.
Impact of Gene Editing on Eli Lilly’s Growth Trajectory
The strategic focus on PCSK9 gene editing could accelerate revenue growth in a high-value therapeutic area, especially if initial trials demonstrate compelling efficacy and safety. However, it also introduces uncertainty, as clinical success is pivotal, and regulatory hurdles could delay market entry.
The acquisition aligns with Eli Lilly’s broader objective to strengthen its pipeline, which bolsters investor confidence in its capacity for innovation-led growth. According to the author, this could positively influence valuation multiples, provided the program meets development milestones.
In the near term, market sentiment toward the stock will likely hinge on updates regarding early-stage data and integration synergies. The author’s thesis emphasizes that these dynamics, along with broader market conditions, could either amplify or temper the stock's price action.

Eli Lilly's Strategic Move: Verve Therapeutics Acquisition and Its Impact on LLY Growth Potential

Eli Lilly's acquisition of Verve Therapeutics signifies a pivotal strategic initiative aimed at cementing its foothold in the cardiovascular treatment sector. By focusing on innovative gene-editing technologies to permanently lower cholesterol levels, this move aligns with growing demand for advanced and long-term healthcare solutions, indicating a strong avenue for future revenue expansion.
Key Factors Shaping LLY's Near-Term Stock Performance
The integration of Verve's cutting-edge therapeutic pipeline enhances Eli Lilly's R&D portfolio and competitive positioning in the biotech space. This development could drive investor confidence, especially as the cardiovascular market is poised for continued growth.
Potential regulatory hurdles and timelines for clinical trials remain critical risks that could moderate immediate market enthusiasm. Nevertheless, the prospect of long-term benefits from exclusive proprietary technologies positions LLY for sustained innovation-driven growth.
Lastly, the transaction underscores Eli Lilly's strategic capital deployment, highlighting prudent investment in high-growth opportunities. Such moves could foster shareholder confidence, particularly among institutional investors seeking exposure to transformative healthcare advancements.

Eli Lilly's Strategic $1.3B Investment in Cardiovascular Breakthroughs: Implications for LLY Stock

Eli Lilly's $1.3 billion investment in Verve Therapeutics underscores its commitment to the rapidly advancing cardiovascular gene therapy market. This move positions Lilly as a frontrunner in addressing significant unmet needs in cardiovascular diseases, with substantial long-term growth potential. The partnership could accelerate drug discovery timelines and enhance diversified revenue streams for the company.
Key Drivers Affecting Eli Lilly's Stock Price
The financial collaboration reflects not just an equity investment but also milestone-based success payments, fostering alignment of incentives between the two companies. This approach limits immediate risk to Lilly while enabling exposure to disruptive biotechnological advancements, which is a positive factor for investor confidence in near-term valuation stability.
The cardiovascular gene therapy space is projected to see exponential growth, bolstered by increasing clinical adoption of advanced genetic editing technologies like CRISPR. By strategically aligning with Verve, Lilly taps into an area with high therapeutic relevance and scalability, likely reinforcing bullish sentiment among institutional investors.
Additionally, ignoring short-term headline risks tied to biotech volatility, this deal highlights Lilly's long-term innovation strategy. Such sustained R&D efforts solidify its competitive position while counterbalancing possible margin compression in other product categories.
Weight loss innovations have emerged as a transformative growth driver for Eli Lilly, with the company's advancements in obesity treatments like Mounjaro positioning it as a market leader in this multi-billion-dollar sector. The author emphasizes that the strong demand and regulatory approvals could lead to significant revenue expansions, potentially redefining the company's core business segments.
Pipeline strength further reinforces Eli Lilly's growth prospects. With promising late-stage drug candidates targeting areas like diabetes, oncology, and neuroscience, the company is strategically diversifying its portfolio, which could act as a robust hedge against market volatility and enhance long-term valuation.
Strategic Market Leadership
Eli Lilly's strategic positioning in the obesity and diabetes treatment markets underscores its market leadership and pricing power. According to the author, the potential for global healthcare policy shifts supporting obesity treatments could further amplify demand and solidify its first-mover advantages.
Valuation metrics and earnings momentum also support a bullish view on the stock. As the author notes, strong earnings growth coupled with expanding operating margins highlights operational efficiency, while valuation relative to peers suggests further upside, especially if weight-loss therapies exceed market expectations.
Recent advancements in targeting the NaV1.8 pathway for pain management reflect Eli Lilly's robust focus on innovation within specialized therapeutics. Leveraging this approach, the company is positioning itself as a leader alongside Vertex Pharmaceuticals, indicating a commitment to addressing unmet medical needs in a competitive market. As noted by the author, success in this domain could potentially create a durable competitive advantage in an area of high medical and commercial value.
Implications for Eli Lilly’s Stock Valuation
The success of pipeline assets targeting the NaV1.8 pathway could translate to a significant long-term revenue stream. However, this progress also carries execution risks, such as clinical trial results and FDA approval hurdles, which may introduce short-term volatility. Additionally, the company's strategic partnerships and investments in cutting-edge therapies signal disciplined capital allocation aimed at high-reward opportunities. The outcome of these incoming clinical milestones will likely serve as key catalysts affecting near-term stock movements.
Broader market dynamics, including increasing competition in the pain management space, could act as an external moderating force on profitability. It remains essential for Eli Lilly to demonstrate leadership through both efficacy data and commercialization strategies to sustain investor confidence. The author underscores these dynamics, highlighting the potential for both risk and reward tied to the company’s innovative focus.
Eli Lilly (LLY) currently faces challenges in sustaining its competitive edge within the pharmaceutical market, particularly in the wake of Novo Nordisk’s recent struggles. The author notes that while Novo Nordisk’s issues could have provided a tailwind for LLY’s stock performance, prevailing concerns about valuation metrics and market saturation have tempered investor optimism.
Valuation Concerns and Competitive Dynamics
The high valuation of Eli Lilly’s stock, which trades at a premium to its peers, has raised questions about its near-term growth potential. The author underscores that without a significant catalyst for growth, such elevated pricing could limit upside opportunities and possibly attract profit-taking in the short term.
Another key factor highlighted is the competitive landscape in the GLP-1 agonist market, where both Eli Lilly and Novo Nordisk are dominant players. While Novo Nordisk’s struggles could reduce competition, Eli Lilly’s ability to capitalize depends on maintaining innovation and gaining further market share, which remains uncertain in the immediate future.
Finally, the pipeline of new product launches, which is often a key growth driver in the pharmaceutical sector, appears to lack near-term revolutionary breakthroughs. As the author points out, this has made it difficult for investors to justify the current elevated valuations absent a clear path to accelerating revenue growth.
The development of Eli Lilly's obesity drug pipeline, with ambitions extending beyond Zepbound, represents a pivotal growth avenue for the company. By addressing a broader spectrum of obesity-related conditions and positioning itself at the forefront of a rapidly expanding market, LLY is set to capitalize on increasing global demand for effective treatments. The author emphasizes the strategic importance of this segment as a potential driver of long-term revenue and margin expansion.
Market Dynamics and Strategic Innovation
LLY's innovative approach within its pipeline underscores the company's commitment to differentiation through clinical advancement. By leveraging proprietary technology and aiming for superior efficacy profiles, the author argues that Eli Lilly is creating a competitive edge that could enhance investor confidence and sustain premium valuation multiples in the near to medium term.
Additionally, the pipeline's diversification mitigates risk by reducing dependency on any single blockbuster drug. This balance not only reinforces financial stability but also signals management's strategic foresight, an element that may positively influence institutional investor sentiment.
The regulatory environment, as noted, could play a dual role. The approval of new treatments would accelerate market penetration, but any unanticipated delays or setbacks may weigh on short-term performance. Still, the overall outlook remains favorable given Eli Lilly's track record of navigating complex regulatory landscapes.
Eli Lilly's stock performance has recently faced downward pressure due to factors such as regulatory challenges and broader market volatility. The author's analysis underscores that the company's strategic pipeline recovery, coupled with its strong presence in the high-demand pharmaceutical sector, provides a foundation for near-term growth despite temporary setbacks.
Key Drivers of Upside Potential
The author highlights Eli Lilly's diversified therapeutic portfolio and promising clinical trials as critical to reclaiming investor confidence. Advanced-stage developments in areas such as diabetes and cancer treatments could lead to renewed revenue momentum, offering significant upside potential for the stock.
Continued demand for innovative treatments and a resilient research pipeline solidify the company's competitive position in its sector. The author further notes Eli Lilly's historical ability to navigate periods of turbulence and deliver shareholder value, suggesting strong management execution.
Operational headwinds, such as pricing pressures and competition, are acknowledged; however, these factors are viewed as temporary hurdles rather than long-term impediments. The author's outlook remains optimistic, reinforced by consistently improving fundamentals.
Eli Lilly's robust pipeline of innovative drugs serves as a critical driver for the company's long-term growth potential. The author notes the near-term catalysts, including highly anticipated developments in diabetes and obesity treatments, which are poised to capture significant market share and enhance revenue streams.
Key Catalysts Driving Confidence in LLY Stock
The company's emphasis on research and development positions it as a leader in addressing high-demand medical conditions. This sustained investment guarantees a competitive edge, as highlighted by the article, contributing to investor optimism.
Eli Lilly's recent earnings growth and consistent performance underscore the resilience of its business model. These aspects reiterate the author's viewpoint that current valuation metrics remain justifiable despite premium pricing.
Management's strategic capital allocation, particularly toward expansion and acquisitions, complements the organic growth initiatives. As the article suggests, this approach aligns with long-term shareholder value creation and mitigates risks associated with over-reliance on single markets.
The exclusion of Zepbound from CVS Health’s formularies is a pivotal financial development, potentially impacting Eli Lilly’s revenue forecasts tied to this specific drug. According to the analysis, the market's reaction appears disproportionate to the scale of this decision in the broader context of Eli Lilly's diversified product portfolio and growth trajectory.
Key Factors Driving Eli Lilly’s Stock Movement
The historical overperformance of Eli Lilly’s stock relative to peers suggests underlying investor confidence in its long-term prospects. However, the 11%+ drop reflects heightened sensitivity to pipeline disruptions and formulary adjustments, signaling that sentiment could see continued volatility.
Despite recent setbacks, Eli Lilly’s robust pipeline, including its innovation in diabetes and obesity treatments, offers a steady stream of growth drivers. The long-term value proposition remains strong as these treatments address high-demand medical needs and demonstrate significant revenue upside potential.
Eli Lilly’s development of Orforglipron, a once-daily oral GLP-1 receptor agonist, signifies a critical breakthrough as it addresses a major patient barrier—the inconvenience of injectable treatments. The author emphasizes that this innovation positions Lilly to capture a larger share of the rapidly expanding GLP-1 market, driving substantial growth potential.
The competitive landscape in the obesity and diabetes treatment markets imposes pressure on pharmaceutical companies to innovate. Eli Lilly’s leadership in the GLP-1 category—with products like Mounjaro—suggests its expertise in leveraging clinical efficacy and safety data, as highlighted by the author, further solidifying its competitive edge.
Strategic Market Opportunities
Lilly’s efforts to expand the product pipeline and deepen penetration into high-growth therapeutic markets underline its robust R&D capabilities. According to the author, Orforglipron strengthens the company’s outlook for scaling revenues, potentially translating into enhanced stock performance.
The macroeconomic backdrop, including widespread demand for obesity treatments, is favorably aligned with Eli Lilly’s advancements. The author notes strategic timing as another positive factor, making the company well-positioned to maximize commercial opportunities in the near term.
Eli Lilly's prospects are significantly bolstered by the anticipated success of Orforglipron, a pivotal drug in their diabetes portfolio. Its potential to capture substantial market share in the growing GLP-1 market positions the company for both near- and long-term revenue expansion. The author highlights this asset as a cornerstone for sustained growth, supported by a well-differentiated product profile that enhances competitive resilience.
Key Catalysts Supporting Stock Momentum
Furthermore, Eli Lilly's existing pharmaceutical lineup continues to outperform, particularly its burgeoning portfolio in oncology and immunology. The strong pipeline and recent regulatory approvals point to robust earnings growth potential, which the author believes could act as a near-term catalyst for the stock.
Operationally, the company maintains a solid financial base with improving gross margins and disciplined cost management. Combined with incremental revenue growth drivers like Orforglipron, these operational efficiencies could reflect positively in upcoming earnings reports, fueling investor confidence.
Finally, macroeconomic tailwinds such as expanding global healthcare demand and the company’s focus on innovation align with long-term growth trends. These factors not only validate Eli Lilly’s current valuation but also strengthen its position in the high-growth pharmaceutical sector.
Comprehensive Analysis of Eli Lilly and Comp. (LLY) Stock Market Performance
Our multifaceted analysis of Eli Lilly and Comp.'s stock market is grounded in the company's key news stories, insights from reputable analysts, as well as mathematical and technical evaluations. Taking into account assessments from each of these aspects in real-time helps us address the most crucial questions for investors in the most objective way possible:
- When should I take profit in Eli Lilly and Comp. stock?
- When should I record a loss on Eli Lilly and Comp. stock?
- What are analysts' forecasts for Eli Lilly and Comp. stock?
- What is the future of Eli Lilly and Comp. stock?
We forecast Eli Lilly and Comp. stock performance using neural networks based on historical data on Eli Lilly and Comp. stocks.
Eli Lilly and Company is an American pharmaceutical company. It was founded in 1876 in Indianapolis, Indiana, where its headquarters are still located. It is known as the first company to start the industrial production of insulin (in 1923). The company operates in two areas: medicines for humans and veterinary medicines (a division of Elanco). The company’s products are sold in 120 countries.
Eli Lilly and Company News influencing stock rates

As of now, Panda has combed through 26 news items directly related to LLY from the last 30 days. Out of these, 16 clearly showcase a bullish trend, while 3 display bearish tendencies, and 7 events are neutral.
Based on an analysis of the most important news from the last 30 days affecting LLY shares, it's clear that bullish sentiments are completely overshadowing bearish ones. The impact of positive news is more than five times as dominant as that of negative developments.
The news analyzed fell within the period from May 22, 2025, to Jun 21, 2025.
Fed Rate Cut Looms, Obesity Drugs Boost LLY, Aflac Faces Cybersecurity Challenge


Obesity Drugs Gain Momentum as Key Heart Disease Preventative – A Boost for Eli Lilly


Biotech M&A Revival Hinges on Interest Rates and Drug Reforms


FDA Appoints Prasad as Chief Medical and Scientific Officer Amid Restructuring


Skye Bioscience Challenges Eli Lilly's GLP-1 Dominance with Nimacimab Updates


Bariatric Surgery Outperforms Eli Lilly’s GLP-1 Drugs in Weight Loss Battle


Scholar Rock and Lilly Combo Shows Promising Weight Loss with Muscle Preservation


FDA's Makary Pushes AI Integration to Fast-Track Drug Reviews


FDA's New Voucher System to Slash Drug Review Times to 2 Months


White House Considers Limits on Pharma Ads, Targeting $10 Billion Market


Eli Lilly and Comp. daily forecast for a month
Date | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jun 23 | 759.88 | 749.62 | 774.69 | 3.35 |
Jun 24 | 761.02 | 749.15 | 774.03 | 3.32 |
Jun 25 | 748.92 | 739.26 | 753.41 | 1.91 |
Jun 26 | 750.94 | 734.49 | 762.65 | 3.83 |
Jun 27 | 750.71 | 739.68 | 767.60 | 3.78 |
Jun 28 | 770.76 | 763.13 | 785.33 | 2.91 |
Jun 29 | 761.97 | 745.51 | 776.83 | 4.20 |
Jun 30 | 769.29 | 754.28 | 784.29 | 3.98 |
Jul 01 | 753.82 | 737.77 | 764.00 | 3.56 |
Jul 02 | 752.69 | 748.18 | 769.85 | 2.90 |
Jul 03 | 743.21 | 729.16 | 750.79 | 2.97 |
Jul 04 | 751.90 | 737.24 | 760.02 | 3.09 |
Jul 05 | 753.48 | 738.34 | 764.79 | 3.58 |
Jul 06 | 743.31 | 731.27 | 757.58 | 3.60 |
Jul 07 | 739.07 | 732.20 | 756.59 | 3.33 |
Jul 08 | 735.31 | 721.63 | 740.82 | 2.66 |
Jul 09 | 727.58 | 719.94 | 735.66 | 2.18 |
Jul 10 | 738.50 | 732.07 | 746.92 | 2.03 |
Jul 11 | 739.83 | 722.52 | 755.14 | 4.52 |
Jul 12 | 722.74 | 717.53 | 734.01 | 2.30 |
Jul 13 | 725.12 | 709.68 | 734.26 | 3.46 |
Jul 14 | 711.42 | 695.84 | 723.37 | 3.96 |
Jul 15 | 715.47 | 698.52 | 722.77 | 3.47 |
Jul 16 | 704.74 | 688.46 | 715.10 | 3.87 |
Jul 17 | 698.40 | 692.74 | 708.25 | 2.24 |
Jul 18 | 718.09 | 704.52 | 725.85 | 3.03 |
Jul 19 | 698.70 | 685.71 | 713.17 | 4.00 |
Jul 20 | 688.85 | 682.65 | 703.53 | 3.06 |
Jul 21 | 670.25 | 665.63 | 676.29 | 1.60 |
Jul 22 | 669.05 | 653.79 | 680.09 | 4.02 |
Eli Lilly and Comp. Daily Price Targets
Eli Lilly and Comp. Stock Forecast 06-23-2025.
Forecast target price for 06-23-2025: $759.88.
Negative dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 3.237%.
Pessimistic target level: 749.62
Optimistic target level: 774.69
Eli Lilly and Comp. Stock Forecast 06-24-2025.
Forecast target price for 06-24-2025: $761.02.
Positive dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 3.215%.
Pessimistic target level: 749.15
Optimistic target level: 774.03
Eli Lilly and Comp. Stock Forecast 06-25-2025.
Forecast target price for 06-25-2025: $748.92.
Negative dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 1.879%.
Pessimistic target level: 739.26
Optimistic target level: 753.41
Eli Lilly and Comp. Stock Forecast 06-26-2025.
Forecast target price for 06-26-2025: $750.94.
Positive dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 3.692%.
Pessimistic target level: 734.49
Optimistic target level: 762.65
Eli Lilly and Comp. Stock Forecast 06-27-2025.
Forecast target price for 06-27-2025: $750.71.
Negative dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 3.638%.
Pessimistic target level: 739.68
Optimistic target level: 767.60
Eli Lilly and Comp. Stock Forecast 06-28-2025.
Forecast target price for 06-28-2025: $770.76.
Positive dynamics for Eli Lilly and Comp. shares will prevail with possible volatility of 2.827%.
Pessimistic target level: 763.13
Optimistic target level: 785.33
LLY (LLY) Monthly Stock Prediction for 2025
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jul. | 786.94 | 739.88 | 837.07 | 11.61 |
Aug. | 752.16 | 722.82 | 819.63 | 11.81 |
Sep. | 754.11 | 724.70 | 831.56 | 12.85 |
Oct. | 681.57 | 634.61 | 699.29 | 9.25 |
Nov. | 603.60 | 587.90 | 626.35 | 6.14 |
Dec. | 598.10 | 546.01 | 630.76 | 13.44 |
Eli Lilly and Comp. forecast for this year
Eli Lilly and Comp. Stock Prediction for Jul 2025
An uptrend is forecast for this month with an optimal target price of $786.941. Pessimistic: $739.88. Optimistic: $837.07
Eli Lilly and Comp. Stock Prediction for Aug 2025
An downtrend is forecast for this month with an optimal target price of $752.159. Pessimistic: $722.82. Optimistic: $819.63
Eli Lilly and Comp. Stock Prediction for Sep 2025
An uptrend is forecast for this month with an optimal target price of $754.114. Pessimistic: $724.70. Optimistic: $831.56
Eli Lilly and Comp. Stock Prediction for Oct 2025
An downtrend is forecast for this month with an optimal target price of $681.568. Pessimistic: $634.61. Optimistic: $699.29
Eli Lilly and Comp. Stock Prediction for Nov 2025
An downtrend is forecast for this month with an optimal target price of $603.597. Pessimistic: $587.90. Optimistic: $626.35
Eli Lilly and Comp. Stock Prediction for Dec 2025
An downtrend is forecast for this month with an optimal target price of $598.104. Pessimistic: $546.01. Optimistic: $630.76
Eli Lilly and Comp. (LLY) Monthly Stock Prediction for 2026
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 639.31 | 611.06 | 662.59 | 7.78 |
Feb | 656.77 | 597.00 | 676.40 | 11.74 |
Mar | 625.18 | 582.92 | 664.19 | 12.24 |
Apr | 692.63 | 620.60 | 756.56 | 17.97 |
May | 677.33 | 644.75 | 728.40 | 11.48 |
Jun | 705.50 | 633.05 | 770.62 | 17.85 |
Jul | 730.27 | 701.79 | 784.38 | 10.53 |
Aug | 700.84 | 666.22 | 739.10 | 9.86 |
Sep | 717.24 | 654.76 | 772.25 | 15.21 |
Oct | 710.71 | 669.13 | 740.27 | 9.61 |
Nov | 713.48 | 667.10 | 778.41 | 14.30 |
Dec | 668.96 | 617.65 | 692.44 | 10.80 |
Eli Lilly and Comp. (LLY) Monthly Stock Prediction for 2027
Month | Target | Pes. | Opt. | Vol., % |
---|---|---|---|---|
Jan | 643.74 | 611.10 | 673.87 | 9.31 |
Feb | 645.41 | 603.46 | 673.10 | 10.35 |
Mar | 563.19 | 547.81 | 601.99 | 9.00 |
Apr | 555.87 | 508.90 | 588.38 | 13.51 |
May | 546.47 | 495.32 | 602.60 | 17.80 |
Jun | 525.87 | 477.33 | 555.27 | 14.04 |
Jul | 529.97 | 509.99 | 573.38 | 11.05 |
Aug | 583.71 | 526.04 | 607.24 | 13.37 |
Sep | 633.04 | 577.07 | 657.72 | 12.26 |
Oct | 610.82 | 553.64 | 673.55 | 17.80 |
Nov | 540.94 | 524.76 | 564.85 | 7.10 |
Dec | 496.64 | 461.77 | 519.88 | 11.18 |
Eli Lilly and Comp. information and performance
LILLY CORPORATE CTR, DROP CODE 1094, INDIANAPOLIS, IN, US
Market capitalization of the Eli Lilly and Company is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of LLY shares in the company outstanding by the market price of one share.
EBITDA of Eli Lilly and Comp. is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
Eli Lilly and Comp. (LLY) stock dividend
Eli Lilly and Comp. last paid dividends on 05/16/2025. The next scheduled payment will be on 06/10/2025. The amount of dividends is $5.4 per share. If the date of the next dividend payment has not been updated, it means that the issuer has not yet announced the exact payment. As soon as information becomes available, we will immediately update the data. Bookmark our portal to stay updated.
Last Split Date: 01/01/1970
Splitting of shares is an increase in the number of securities of the issuing company circulating on the market due to a decrease in their value at constant capitalization.
For example, a 5: 1 ratio means that the value of one share will decrease 5 times, the total amount will increase 5 times. It is important to understand that this procedure does not change the capitalization of the company, as well as the total value of assets held in private hands.
FAQ (Frequently Asked Questions about Eli Lilly and Comp. Stock)
Should I Buy Eli Lilly and Comp. Shares in 2025 year?
Does Eli Lilly and Comp. pay dividends?
Which economic sector do Eli Lilly and Comp.'s shares belong to?
Which other securities belong to the same sector as Eli Lilly and Comp.'s shares?
Related stocks from Healthcare sector
All forecast data on the site are provided for informational purposes of using neural forecasting tools in the financial market and are not a call to action and, moreover, are not trading signals. When using the forecast data, the investor assumes all financial risks. The pandaforecast.com portal is not responsible for the loss of your money in the stock market as a result of using the information contained on the site.